Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions

American Journal of Pathology

Volumn 153, Issue 6, 1998, Pages 1741-1748

  Sano, Takaaki ^a   Oyama, Tetsunari ^a   Kashiwabara, Kenji ^a   Fukuda, Toshio ^a   Nakajima, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ARTICLE; CARCINOGENESIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 0031740497     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65689-1     Document Type: Article

References (45)

1. zur Hausen H: Papillomavirus infections: a major cause of human cancers. Biochim Biophys Acta 1996, 1288:F55-F78
2. Lorincz AT, Reid R, Bennett Jenson A, Greenberg MD, Lancaster W, Kurman RJ: Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992, 79:328-337
3. Matsukura T, Sugase M: Identification of genital human papillomaviruses in cervical biopsy specimens: segregation of specific virus types in specific clinicopathologic lesions. Int J Cancer 1995, 61: 13-22
4. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT: HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989, 8:3905-3910
5. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63:4417-4421
6. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248: 76-79
7. Dyson N, Howley PM, Munger K, Harlow E: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937
8. Bagchi S, Raychaudhuri P, Nevins JR: Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 1990, 62: 659-669
9. Lechner MS, Mack DH, Finicle AB, Crook T, Vousden KH, Laimins LA: Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 1992, 11:3045-3052
10. Phelps WC, Yee CL, Munger K, Howley PM: The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988, 53:539-547
11. Amortegui AJ, Meyer MP, Elborne VL, Amin RM: P53, retinoblastoma gene product, and cyclin protein expression in human papillomavirus virus DMA-positive cervical intraepithelial neoplasia and invasive cancer. Mod Pathol 1995, 8:907-912
12. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
13. Koh J, Enders GH, Dynlacht BD, Harlow E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995, 375:506-510
14. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, Rollins BJ: Reciprocal Rb inactivation and p16 expression in primary lung cancers and cell lines. Cancer Res 1995, 55:505-509
15. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon HE, Komoto Y, Kusafuka T, Okada A, Matsuda H: Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers. Int J Cancer 1996, 65:442-445
16. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J: Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer Res 1996, 56:3415-3420
17. Kinoshita I, Dosaka-Akita H, Mishima T, Akie K, Nishi M, Hiroumi H, Hommura F, Kawakami Y: Altered p16 and retinoblastoma protein status in non-small cell lung cancer. Cancer Res 1996, 56:5557-5562
18. Piccinin S, Doglioni C, Maestro R, Vukosavljevic T, Gasparotto D, D'Orazi C, Boiocchi M: P16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression. Int J Cancer 1997, 74:26-30
19. Papadimitrakopoulou V, Izzo J, Lippman SM, Lee JS, Fan YH, Clayman G, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L: Frequent inactivation of p16INK4a in oral premalignant lesions. Oncogene 1997, 14:1799-1803
20. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996, 56:3630-3633
21. Geradts J, Wilson PA: High frequency of aberrant p16 INK4a expression in human breast cancer. Am J Pathol 1996, 149:15-20
22. Geradts J, Kratzke RA, Niehans GA, Lincoln CE: Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16 in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995, 55:6006-6011
23. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T: Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 1994, 54:3042-3048
24. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T: Immunohistochemical overexpression of p16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia. Pathol Int 1998, 48:580-585
25. Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamoto K, Yokota J: Deletion map of chromosome 9 and p16(CDKN2A) gene alterations in neuroblastoma. Cancer Res 1997, 57:907-912
26. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, Howley PM: Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996, 93:4350-4354
27. Sano T, Hikino T, Niwa Y, Kashiwabara K, Oyama T, Fukuda T, Nakajima T: In situ hybridization with biotinylated tyramide amplification: detection of human papillomavirus DNA in cervical neoplastic lesions. Mod Pathol 1998, 11:19-23
28. Kerstens HMJ, Poddighe PJ, Hanselaar AGJM: A novel in situ hybridization signal amplification method based on the deposition of biotinylated tyramine. J Histochem Cytochem 1995, 43:347-352
29. Cooper K, Herrington CS, Stickland JE, Evans MF, McGee JOD: Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridization. J Clin Pathol 1991, 44: 990-996
30. Cooper K: Nonisotopic in situ hybridization in the detection of integrated HPV 16/18 in cervical cancers. Hum Pathol 1996, 27:745
31. Sano T, Sakurai S, Fukuda T, Nakajima T: Unsuccessful effort to detect human papillomavirus DNA in urinary bladder cancers by the polymerase chain reaction and in situ hybridization. Pathol Int 1995, 45:506-512
32. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A: Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991, 82:524-531
33. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN: Molecular genetic correlates of p16, cdk4 and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998, 57:122-130
34. Kashiwabara K, Oyama T, Sano T, Fukuda T, Nakajima T: Correlation between methylation status of the p16/CDKN2 gene and the expression of p 16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 1998, 79:215-220
35. Choo K-B, Chang KY: Absence of mutation in the p53 and the retinoblastoma genes in primary cervical carcinomas. Virology 1993, 193:1042-1046
36. Kelley MJ, Otterson GA, Kaye FJ, Popescue NC, Johnson BE, Dipaolo JA: CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 1995, 63:226-230
37. Hirama T, Miller CW, Wilczynski SP, Koeffler HP: P16 (CDKN2/cyclin-dependent kinase-4 inhibitor/multiple tumor suppressor-1) gene is not altered in uterine cervical carcinomas or cell lines. Mod Pathol 1996, 9:26-31
38. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang S-C, Pater MM, Pater A: Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Br J Cancer 1997, 75:1410-1416
39. Andl T, Kahn T, Pfuhl A, Nicola T, Erber R, Conradt C, Klein W, Helbig M, Dietz A, Weidauer H, Bosch FX: Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 1998, 58:5-13
40. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G, Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 1998, 79:71-75
41. Choo KB, Lee HH, Pan CC, Wu SM, Liew LN, Cheung WF, Han SH: Sequence duplication and internal deletion in the integrated human papillomavirus type 16 genome cloned from a cervical carcinoma. J Virol 1988, 62:1659-1666
42. Gage JR, Meyers C, Wettstein FO: The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b), and of the oncogenic HPV-16 differ in retinoblastoma protein binding, and other properties. J Virol 1990, 46:723-730
43. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C: Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995, 55:493-497
44. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA, Stadler WM: Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 1996, 56:2886-2890
45. Xiong Y, Kuppuswamy D, Li Y, Livanos EM, Hixon M, White A, Beach D, Tlsty TD: Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation. J Virol 1996, 70:999-1008